Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Non-Current Debt (2019 - 2020)

Ovid Therapeutics filings provide 2 years of Non-Current Debt readings, the most recent being $61200.0 for Q4 2020.

  • Quarterly Non-Current Debt fell 78.64% to $61200.0 in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $61200.0 through Dec 2020, down 78.64% year-over-year, with the annual reading at $61200.0 for FY2020, 78.64% down from the prior year.
  • Non-Current Debt hit $61200.0 in Q4 2020 for Ovid Therapeutics, roughly flat from $61200.0 in the prior quarter.
  • Across five years, Non-Current Debt topped out at $1.3 million in Q1 2019 and bottomed at $61200.0 in Q3 2020.